Considerations in Pediatric Overactive Bladder



Overactive bladder is a term used to describe the symptoms of urgency with or without urgency incontinence that is not the direct result of a known neurologic abnormality. This troublesome condition has a prevalence of as high as 15–20% of the pediatric population, with 2–4% of 7-year-old children reporting incontinence episodes at least once a week. The main objectives of treatment are to normalize the micturition pattern, bladder and pelvic floor overactivity, and cure incontinence. Treatment follows a stepwise, multimodal approach including behavioral modification, adjunctive biofeedback, and in refractory cases, pharmacotherapy. This review will outline the pharmacologic treatment options for pediatric overactive bladder in cases where conservative management has proven unsuccessful.


Pediatric overactive bladder Urgency incontinence Detrusor hyperreflexia Oxybutynin Anticholinergics Mirabegron β3-agonist Onabotulinum toxin 


  1. 1.
    Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children’s Continence Society. Neurourol Urodyn. 2016;35(4):471–81.CrossRefGoogle Scholar
  2. 2.
    Nijman R, Tekgul S, Chase J, Bael A, Austin P, von Gontard A. Diagnosis and management of urinary incontinence in childhood. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence, 5th ed. 5th International Consultation on Incontinence, Paris, February; 2012. p. 729–826. The International Continence Society (ICS) and the International Consultation on Urological Diseases (ICUD); 2013.Google Scholar
  3. 3.
    Järvelin MR, Vikeväinen-Tervonen L, Moilanen I, Huttunen NP. Enuresis in seven-year-old children. Acta Paediatr Scand. 1998;77(1):148–53.CrossRefGoogle Scholar
  4. 4.
    Sureshkumar P, Craig JC, Roy LP, Knight JF. Daytime urinary incontinence in primary school children: a population-based survey. J Pediatr. 2000;137(6):814–8.CrossRefGoogle Scholar
  5. 5.
    Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study. Int J Urol. 2006;13(1):36–41.CrossRefGoogle Scholar
  6. 6.
    Chung JM, Lee SD, Kang DI, Kwon DD, Kim KS, Kim SY, et al.; Korean Enuresis Association. Prevalence and associated factors of overactive bladder in Korean children 5–13 years old: a nationwide multicenter study. Urology 2009;73(1):63–7; discussion 68-9.CrossRefGoogle Scholar
  7. 7.
    Hellstrom AL, Hjalmas K, Jodal U. Rehabilitation of the dysfunctional bladder in children: method and 3-year follow-up. J Urol. 1987;138(4):847–9.CrossRefGoogle Scholar
  8. 8.
    Halliday S, Meadow SR, Berg I. Successful management of daytime enuresis using alarm procedures: a randomly controlled trial. Arch Dis Child. 1987;62(2):132–7.CrossRefGoogle Scholar
  9. 9.
    Vasconcelos M, Lima E, Caiafa L, Noronha A, Cangussu R, Gomes S, et al. Voiding dysfunction in children. Pelvic-floor exercises or biofeedback therapy: a randomized study. Pediatr Nephrol. 2006;21(12):1858–64.CrossRefGoogle Scholar
  10. 10.
    Kroll P. Pharmacotherapy for pediatric neurogenic bladder. Pediatr Drugs. 2017;19(5):463–78.CrossRefGoogle Scholar
  11. 11.
    Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243–85.CrossRefGoogle Scholar
  12. 12.
    Blais AS, Bergeron M, Nadeau G, Ramsay S, Bolduc S. Anticholinergic use in children: persistence and patterns of therapy. Can Urol Assoc J. 2016;10(3–4):137–40.CrossRefGoogle Scholar
  13. 13.
    Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.CrossRefGoogle Scholar
  14. 14.
    Gish P, Mosholder AD, Truffa M, Johann-Liang R. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. J Pediatr. 2009;155(3):432–4.CrossRefGoogle Scholar
  15. 15.
    Robinson D, Giarenis I, Cardozo L. New developments in the medical management of overactive bladder. Maturitas. 2013;76(3):225–9.CrossRefGoogle Scholar
  16. 16.
    Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62(6):1040–60.CrossRefGoogle Scholar
  17. 17.
    Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;18(1):CD005429.Google Scholar
  18. 18.
    Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, Artibani W. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–63.CrossRefGoogle Scholar
  19. 19.
    Chang SJ, Van Laecke E, Bauer SB, von Gontard A, Bagli D, Bower WF, et al. Treatment of daytime urinary incontinence: a standardization document from the International Children’s Continence Society. Neurourol Urodyn. 2017;36(1):43–50.CrossRefGoogle Scholar
  20. 20.
    Baek M, Kang JY, Jeong J, Kim DK, Kim KM. Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia. Int Urol Nephrol. 2013;45(3):703–9.CrossRefGoogle Scholar
  21. 21.
    Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology. 2002;59(3):428–32.CrossRefGoogle Scholar
  22. 22.
    Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol. 2009;182(4):1548–54.CrossRefGoogle Scholar
  23. 23.
    Franco I, Horowitz M, Grady R, Adams RC, De Jong T, Lindert K, Albrecht D. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol. 2005;173(1):221–5.CrossRefGoogle Scholar
  24. 24.
    Noronha-Blob L, Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and m3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991;256(2):562–7.PubMedGoogle Scholar
  25. 25.
    Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Assoc J. 2017;1(1–2 Suppl 1):S74–9.CrossRefGoogle Scholar
  26. 26.
    Curran MJ, Kaefer M, Peters C, Logigian E, Bauer SB. The detrusor overactivity in childhood: long-term results with conservative management. J Urol. 2000;163(2):574–7.CrossRefGoogle Scholar
  27. 27.
    Gleason JM, Daniels C, Williams K, Varghese A, Koyle MA, Bägli DJ, et al. Single-center experience with oxybutynin transdermal system (patch) for the management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well-tolerated alternative form of administration. J Pediatr Urol. 2014;10(4):753–7.CrossRefGoogle Scholar
  28. 28.
    Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol. 1991;146(2 Pt 2):532–4.CrossRefGoogle Scholar
  29. 29.
    Ellsworth PI, Borgstein NG, Nigman RJ, Reddy PP. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. J Urol. 2005;174(4 Pt 2):1647–51.CrossRefGoogle Scholar
  30. 30.
    Goessl C, Sauter T, Michael T, Berge B, Staehler M, Miller K. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology. 2000;55(3):414–8.CrossRefGoogle Scholar
  31. 31.
    Hjälmås K, Hellström AL, Mogren K, Läckgren G, Stenberg A. The overactive bladder in children: a potential future indication for tolterodine. BJU Int. 2001;87(6):569–74.CrossRefGoogle Scholar
  32. 32.
    Bolduc S, Upadhyay J, Payton J, Bagli DJ, McLorie GA, Khoury AE, Farhat W. The use of tolterodine in children after oxybutynin failure. BJU Int. 2003;91(4):398–401.CrossRefGoogle Scholar
  33. 33.
    Nijman RJ, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol. 2005;173(4):1334–9.CrossRefGoogle Scholar
  34. 34.
    Nijman RJ, Borgstein NG, Ellsworth P, Siggaard C. Long-term tolerability of tolterodine extended release in children 5–11 years of age: results from a 12-month, open-label study. Eur Urol. 2007;52(5):1511–6.CrossRefGoogle Scholar
  35. 35.
    Reinberg Y, Crocker J, Wolpert J, Vandersteen D. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol. 2003;169(1):317–9.CrossRefGoogle Scholar
  36. 36.
    Bolduc S, Moore K, Nadeau G, Lebel S, Lamontage P, Hamel M. Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010;184(4 Suppl):1668–73.CrossRefGoogle Scholar
  37. 37.
    Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, Vande WJ. Solfenacin for therapy resistant overactive bladder. J Urol. 2009;182(4 Suppl):2040–4.CrossRefGoogle Scholar
  38. 38.
    Lopez Pereira P, Miguelez C, Caffarati J, Estornell F, Anduera A. Trospium chloride for the treatment of detrusor instability in children. J Urol. 2003;170(5):1978–81.CrossRefGoogle Scholar
  39. 39.
    Marschall-Kehrel D, Feustel C, Persson de Geeter C, Stehr M, Radmayr C, Sillén U, Strugala G. Treatment with propiverine in children suffering from non-neurogenic overactive bladder and urinary incontinence: results of a randomized, placebo-controlled, phase 3 clinical trial. Eur Urol. 2009;55(3):729–36.CrossRefGoogle Scholar
  40. 40.
    Nadeau G, Schröder A, Moore K, Genois L, Lamontagne P, Hamel M, et al. Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: long-term results of a prospective, open-label study. Can Urol Assoc J. 2014;8(5–6):175–80.CrossRefGoogle Scholar
  41. 41.
    Fahmy A, Youssif M, Rhashad H, Mokhless I, Mahfouz W. Combined low-dose antimuscarinics for refractory detrusor over-activity in children. J Ped Urol. 2016;12(4):219.e1–5.CrossRefGoogle Scholar
  42. 42.
    Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70(1):9–13.CrossRefGoogle Scholar
  43. 43.
    Morin F, Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Dual therapy for refractory overactive bladder in children: a prospective open-label study. J Urol. 2017;197(4):1158–63.CrossRefGoogle Scholar
  44. 44.
    Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al.; European Consensus Panel. Recommendations on the use of onabotulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55(1):100–19.Google Scholar
  45. 45.
    Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2003;44(1):139–43.CrossRefGoogle Scholar
  46. 46.
    Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, Van Laecke E. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol. 2006;176(1):328–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of UrologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations